Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
63
datasets available to search
ShareScore release 0.9.0
Dataset results
63 results for “Alzheimer's disease','PET”
Impact of Image Processing Settings for Radiomic Features in Alzheimer's Disease Using 18F-FDG and 11C-PIB PET Scans
<p>Radiomics is an established method for calculating features for computer-aided diagnosis and has been vastly applied to oncological studies. This study aimed to assess the impact of image processing in radiomic features in neuroimaging. Fifteen Alzheimer's disease subjects and 18 healthy individuals underwent [18F]-2-fluoro-2-deoxy-D-glucose (FDG) and 11C-labelled Pittsburgh Compound B (PIB) PET scans. T1-MRI scans were used for cerebellar and grey matter (GM), and white matter (WM) tissue delineation. PET images were registered to MRI (MR space) and transformed to MNI space. All images were normalized to cerebellar uptake (SUVR). All possible combinations of the following settings were considered to extract feature values: (1)tracer: FDG or PIB; (2)space: MR or MNI space; (3)discretization: fixed bin number (BN) of 64, fixed bin sizes (BS) of 0.05 or 0.25; and (4)volume of interest (VOI): GM, WM, or BRAIN (GM+WM). Features that correlated (>0.9) to traditional metrics (average VOI SUVR and volume) in any configuration were removed. Correlation of feature values between configurations, redundancy, and harmonization of feature values were tested. Image processing settings highly affect radiomic feature values and should be carefully taken into consideration during study design and should be properly reported.</p><p> </p><p>The enclosed datasets refer to the work developed at the University Medical Center Groningen and consists of extracted feature values used in the publication.</p>
Processed FDG-PET data from: A computational model of neurodegeneration in Alzheimer's disease
<p>Disruption of mental functions in Alzheimer's disease (AD) and related disorders is accompanied by selective degeneration of brain regions. These regions comprise large-scale ensembles of cells organized into systems for mental functioning, however the relationship between clinical symptoms of dementia, patterns of neurodegeneration, and functional systems is not clear. We developed a model of the association between dementia symptoms and degenerative brain anatomy using F18-fluorodeoxyglucose (FDG) PET and dimensionality reduction techniques patients with AD. This data and code package contains preprocessed FDG-PET images from 423 subjects across the Alzheimer's disease spectrum and the MATLAB code to produce eigenbrains from this data.</p>
Data from: Flortaucipir PET uncovers relationships between tau and β-amyloid in aging, primary age related tauopathy, and Alzheimer disease
<p>[<sup>18</sup>F]-Flortaucipir PET is considered a good biomarker of Alzheimer's disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by β-amyloid. It is also unclear whether flortaucipir can detect tau in definite primary age-related tauopathy (PART). We identified 248 individuals at Mayo Clinic that had undergone [<sup>18</sup>F]-flortaucipir PET during life, had died, and undergone an autopsy, 239 cases of which also had β-amyloid PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage and Thal β-amyloid phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with high β-amyloid phase. Flortaucipir uptake linearly increased with β-amyloid phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer's disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART and imaging defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored histopathological tau distribution, were influenced by β-amyloid phase, and were useful for distinguishing different ADNC scores and PART.</p>
Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies
<p>In Alzheimer’s Disease (AD) dual-tracer positron emission tomography (PET) studies with 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose (FDG) and <sup>11</sup>C-labelled Pittsburgh Compound B (PIB) are used to assess metabolism and cerebral amyloid-β deposition, respectively. Regional cerebral metabolism and blood flow (rCBF) are closely coupled, both providing an index for neuronal function. The present study compared PIB-derived rCBF, estimated by the ratio of tracer influx in target regions relative to reference region (<em>R</em><sub>1</sub>) and early-stage PIB uptake (ePIB), to FDG scans. Fifteen PIB positive (+) patients and fifteen PIB negative (-) subjects underwent both FDG and PIB PET scans to assess the use of <em>R</em><sub>1 </sub>and ePIB as a surrogate for FDG. First, subjects were classified based on visual inspection of the PIB PET images. Then, discriminative performance (PIB+ versus PIB-) of rCBF methods were compared to normalized regional FDG uptake. Strong positive correlations were found between analyses, suggesting that PIB-derived rCBF provides information that is closely related to what can be seen on FDG scans. Yet group related differences between method’s distributions were seen as well. Also, a better correlation with FDG was found for <em>R</em><sub>1</sub> than for ePIB. Further studies are needed to validate the use of <em>R</em><sub>1</sub> as an alternative for FDG studies in clinical applications.</p> <p>The enclosed dataset refers to the work developed at the University Medical Center Groningen and consists of all the data retrieved from the PET images and from clinical assessment used in this work.</p>
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
ClinicalTrials.gov study NCT00750282. IPD Sharing: Not stated. Countries: 5. Publications: 2.
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT02423122. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
ClinicalTrials.gov study NCT02167256. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
ClinicalTrials.gov study NCT03901105. IPD Sharing: NO. Countries: 1. Publications: 1.
Processed FDG-PET data from: A computational model of neurodegeneration in Alzheimer’s disease
Open the record for dataset details and reuse information.
Data from: Flortaucipir PET uncovers relationships between tau and β-amyloid in aging, primary age related tauopathy, and Alzheimer disease
Open the record for dataset details and reuse information.
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
ClinicalTrials.gov study NCT03625128. IPD Sharing: Not stated. Countries: 1. Publications: 1.
[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease
ClinicalTrials.gov study NCT06141356. IPD Sharing: NO. Countries: 1. Publications: 1.
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
ClinicalTrials.gov study NCT02370524. IPD Sharing: Not stated. Countries: 1. Publications: 4.
PET Changes in Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT00094913. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease
ClinicalTrials.gov study NCT02330510. IPD Sharing: Not stated. Countries: 1. Publications: 6.
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
ClinicalTrials.gov study NCT02649985. IPD Sharing: NO. Countries: 1. Publications: 1.
F 18 T807 Tau PET Imaging of Alzheimer's Disease
ClinicalTrials.gov study NCT02414347. IPD Sharing: NO. Countries: 1. Publications: 9.
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
ClinicalTrials.gov study NCT02640092. IPD Sharing: Not stated. Countries: 1. Publications: 3.
CSF synaptic biomarkers in the preclinical stage of Alzheimer's disease and their association with MRI and PET markers of neurodegeneration: a cross-sectional study
<p>Objective: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer's <i>continuum</i> and associated with Alzheimer's disease (AD) risk factors, primary pathology, and neurodegeneration markers.</p> <p>Methods: Cross-sectional study in the ALFA+ cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and GAP-43 were measured using immunoassays and SNAP-25 and synaptotagmin-1 using immunoprecipitation mass spectrometry. AD CSF biomarkers Aβ42/40, p-tau and t-tau, and the neurodegeneration biomarker NfL were also measured. Participants underwent structural MRI, and <span>fluorodeoxyglucose and</span> Aβ<span> PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, </span>Aβ<span> pathology, tau pathology, and neurodegeneration markers.</span></p> <p>Results: All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in <i>APOE-</i>ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values) and, importantly, the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism, but lower cortical thickness in AD-related brain regions.</p> <p>Conclusion: CSF synaptic biomarkers increase in early preclinical stages of the Alzheimer's <i>continuum </i>even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, <i>APOE-</i>ε4<i>,</i> and markers of neurodegeneration.</p>
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT00702143. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.